Skip to content

Study · Non-randomized trial · n = 5 · 1986

3 results

The effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short stature.

Borkenstein M

Acta endocrinologica. Supplementum1 Jan 1986Cited by 6 (Europe PMC)

PMID2877535 (opens in a new tab)DOI10.1530/acta.0.112s135 (opens in a new tab)PepBankPUB-02877535
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In five prepubertal children with short stature, intranasal GRF 1-29-NH2 induced a prompt rise of serum GH, peaking at 15 minutes in all children.

    In plain wordsIn five short children, a GRF nasal dose quickly raised growth hormone, with a peak at 15 minutes in every child.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH rise after intranasal GRF 1-29-NH2
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms/kg body weight · intranasalAs given in this study (human).

    Measurements

    Peak serum GH
    28.3 ng/ml
    mean, intranasal GRF 1-29-NH2
    Time to peak serum GH
    15 minutes
    all children

    Source sentences

    Summary
    GRF 1-29-NH2 induced a prompt rise of serum GH levels with peak values at 15 minutes in all children investigated. Peak serum GH values were 28.3 +/- 12.0 ng/ml (mean +/- SD), range 17.1 - 47.6 ng/ml; delta GH was 27.0 +/- 12.2 ng/ml (mean +/- SD).
    1 context sentence
    Summary · context
    The effects of intranasal insufflation of the synthetic growth hormone releasing factor GRF 1-29-NH2 on serum growth hormone (GH) were investigated in five healthy prepubertal children with short stature.
  2. 02HumanNon-randomized trialEfficacy outcome

    In five children with short stature, serum GH levels were still significantly raised 120 minutes after intranasal GRF 1-29-NH2.

    In plain wordsIn five short children, growth hormone was still raised two hours after the GRF nasal dose.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH at 120 minutes after insufflation
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms/kg body weight · intranasalAs given in this study (human).

    Measurements

    Time point of raised serum GH
    120 minutes
    after insufflation

    Source sentences

    Summary
    Serum GH levels were still significantly raised 120 minutes after the insufflation of GRF 1-29-NH2 (p less than 0.05).
    1 context sentence
    Summary · context
    The effects of intranasal insufflation of the synthetic growth hormone releasing factor GRF 1-29-NH2 on serum growth hormone (GH) were investigated in five healthy prepubertal children with short stature.
  3. 03HumanNon-randomized trialSafety outcome

    In five children, no side effects were observed except burning of the nasal mucosa in one patient.

    In plain wordsIn five children, the only side effect was burning of the nose lining in one child.

    Peptide
    Sermorelin
    Outcome
    Not applicableSide effects of intranasal GRF 1-29-NH2
    Study

    n = 5

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    100 micrograms/kg body weight · intranasalAs given in this study (human).

    Source sentences

    Summary
    No side effects, except for burning of the nasal mucosa in one patient, were observed.
    1 context sentence
    Summary · context
    The effects of intranasal insufflation of the synthetic growth hormone releasing factor GRF 1-29-NH2 on serum growth hormone (GH) were investigated in five healthy prepubertal children with short stature.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.